By M. Marin
OTCQB:AINMF
READ THE FULL AINMF RESEARCH REPORT
Benefits of NetraMark’s AI de-risking solutions for clinical research
NetraMark (OTCQB:AINMF), an AI company developing AI and Machine Learning (ML) solutions to help optimize pharmaceutical clinical research trial activities, is entering 2026 with a strong foundation to support its growth following the substantial progress the company made in 2025 across commercial execution, regulatory engagement, and scientific validation that illustrates AINMF’s growing momentum, we believe. For example, NetraMark's contract backlog grew to roughly C$2.5 million in 4Q25, fueled by new project commitments as awareness of and interest in the company’s NetraAI platform builds. The company believes its ongoing momentum supports its goal to attain C$8 - $10 million in contract backlog by mid-2026. The company remains focused on entering into new contracts, shortening sales cycles, and helping sponsors de-risk late-stage trials, among other goals.
Among the multiple partnerships NetraMark formed in 2025, expected to contribute to backlog and revenue, NetraMark completed global Contract Research Organization (CRO) Worldwide Clinical Trial’s onboarding and quality assurance process in mid-October following their execution of a master services agreement in April 2025 to introduce a new service offering for Worldwide's customers powered by NetraMark's NetraAI platform to optimize clinical trial efficiencies. Worldwide Clinical Trials is a full-service global CRO with a footprint that reaches more than 60 countries and about 30 years of clinical experience. Its focus on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory diseases aligns with NetraMark’s focus on CNS and the oncology space.
Going forward, NetraMark can now be included in Worldwide’s Phase 2 and Phase 3 bids across Central Nervous System (CNS) and oncology trials, an important factor expected to contribute to reaching the above-noted C$8 - $10 million contract backlog target. The partners expect to use the NetraMark technology across all therapeutic areas and trial phases in the future. Netramark has signed multiple other contracts and partnerships that we believe position NetraMark for strong revenue advances in 2026 and beyond.
As AINMF continues to build awareness of its capabilities, last month the company announced that its peer-reviewed scientific study highlighting NetraAI was accepted for publication in npj Digital Medicine, part of the Nature Portfolio. The company believes that acceptance by the Nature journal provides third-party validation of NetraMark’s scientific approach. Moreover, in 4Q25 NetraMark, in collaboration with the Centre for Addiction and Mental Health (CAMH), was awarded a prestigious Ontario Research Fund – Research Excellence (ORF-RE) Award, recognizing innovative research partnerships in Ontario. The collaboration will deploy NetraAI within CAMH’s secure computing environment to analyze genetic and epigenetic data in schizophrenia and major depressive disorder, focusing on identifying explainable patient subpopulations. AINMF expects the results to further strengthen NetraAI’s capabilities in psychiatric indications and its relevance for pharmaceutical sponsors.
Recent Critical Path Innovation Meeting (CPIM) With FDA
Separately, the company had submitted a request for and was granted a Critical Path Innovation Meeting (CPIM) with the FDA. NetraMark’s objective was to confirm that the methodologies for clinical trial designs of its AI-driven platform align with and are compliant with the goals and expectations of the FDA and other regulatory bodies.
The CPIM took place last month. The FDA provided feedback on NetraMark’s AI/ML platform, NetraAI, and discussed its application as an enrichment methodology in clinical trial design. The FDA provided feedback on NetraAI’s approach and discussed considerations for identifying responder-enriched subgroups consistent with FDA enrichment guidance. The FDA also suggested that NetraMark consider exploring the MIDD, the FDA’s Model-Informed Drug Development (MIDD) Paired Meeting Program, as a path for scientific dialogue alongside a pharmaceutical sponsor. CPIM discussions do not constitute FDA endorsements, but the feedback and exchange with the FDA potentially could accelerate its expected growth prospects and facilitate adoption of its technology by pharma and CRO partners.
Cost & timelines underscore importance of optimizing clinical activities
The importance of optimizing clinical activities is seen in industry statistics. Billions of dollars are spent on clinical activities to attain regulatory approval for a novel therapy, and yet the success rate of ultimately attaining regulatory approval is extremely low. Specifically, according to McKinsey, “From 2012 to 2022, inflation-adjusted [pharmaceutical] industry R&D spending increased 44 percent, from about $170 billion to $247 billion…” Market research firm Nova One Advisor forecasts that phased clinical trial spending will reach $153.59 billion by 2033, up from an estimated roughly $87 billion in 2024. This would represent a CAGR of 6.49% from 2024 to 2033. The market research firm‘s projections do not include the significant pre-clinical spending that precedes Phase 1.
Considering the cost and timeline to develop a new drug, bring it to regulatory approval, and commercialization (an average of 10-15 years at a cumulative investment of $2.6 billion[1]), PhRMA notes that less than 12% of candidates that commence Phase 1 clinical trials are ultimately approved by the FDA.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
[1]PhRMA (the Pharmaceutical Research and Manufacturers of America trade association)